Development
Dyne Therapeutics, Inc.
DYN
$10.47
$0.222.15%
NASDAQ
| 12/31/2023 | 09/30/2023 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 25.95% | -7.68% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.70% | -6.69% | |||
| Operating Income | -8.70% | 6.69% | |||
| Income Before Tax | -10.68% | 7.23% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -10.68% | 7.23% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.68% | 7.23% | |||
| EBIT | -8.70% | 6.69% | |||
| EBITDA | -8.81% | 6.73% | |||
| EPS Basic | -10.16% | 9.16% | |||
| Normalized Basic EPS | -10.13% | 9.16% | |||
| EPS Diluted | -10.16% | 9.16% | |||
| Normalized Diluted EPS | -10.13% | 9.16% | |||
| Average Basic Shares Outstanding | 0.46% | 2.13% | |||
| Average Diluted Shares Outstanding | 0.46% | 2.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||